Brought to you by 
Arsia, Biogen partner in subcutaneous hemophilia therapies
19 Sep 2017
Executive Summary
Arsia Therapeutics Inc. and Biogen Inc. are teaming up to develop subcutaneously administered hemophilia treatments as an alternative to the current intravenous therapies.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Transdermal
-
Drug Delivery
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Arsia, Biogen partner in subcutaneous hemophilia therapies
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice